CLINICAL-STAGE PIPELINE

Lenzilumab

Ifabotuzumab

HGEN005

Indication

Phase

Status

Centers

Partners

47 sites

3

Undisclosed

Up to 23 sites

2

10 sites

Including MD Anderson and other ZUMA-1 sites

ZUMA-19

Break CAR-T Efficacy/Toxicity Linkage
Lenz prophylaxis as sequenced therapy with Yescarta in r/r DLBCL

Phase Ib/II

1

Active, recruiting

Chronic myelomonocytic leukemia (CMML)
Lenz + azacitidine in NRAS, KRAS or CBL mutant-positive newly-diagnosed patients

Phase II

Advanced Planning

Prevention/Treatment of Acute GvHD
Allogeneic HSCT

Phase II/III

Advanced Planning

Eosinophilic Asthma (EA)
Lenz in inadequately controlled asthma

Phase II

Completed, seeking partner for Phase III

CMML
Lenz monotherapy in salvage patients

Phase I

Completed

To Be Determined

COVID-19

Lenz in prevention/treatment of cytokine storm leading to acute respiratory distress syndrome (ARDS)

Phase III

Planning

4

Solid Tumors

(Glioblastoma Multiforme)

Phase I

Active, almost fully recruited

EA and other eosinophilic diseases

Preclinical

Seeking partner for Phase I/II

1 Phase III may not be necessary for approval in ZUMA-19; precedent is CAR-Ts to date have been approved on Phase II data

2 UK

3 US, EU, Australia

4 Australia

  • Twitter

©2020 Humanigen, Inc.  All rights reserved